Changing the World through Tech

Nominet Trust proudly announced that Reverse the Odds has been named among the 2014 Nominet Trust 100 (NT100) - a global list of 100 inspiring ventures from around the world.

Dr Anne Kiltie hopes to understand when patients diagnosed with muscle invasive bladder cancer are more likely to respond to radiotherapy or should be offered surgery.

Projects featured on the list are using technology to tackle some of the world’s biggest social problems from education and human rights abuses to climate change and health.

Professor Gillies McKenna Receives Gold Medal

Professor Gillies McKenna, Head of the Department of Oncology, has been awarded the Gold Medal by the Royal College of Radiologists in recognition of the outstanding contribution that he has made to the field of radiation oncology.

At the award ceremony, held in London in November 2014, Professor McKenna also delivered the twelfth David Skeggs lecture, entitled Imaging and Targets: The Molecular Frontiers in Radiation Oncology.

Oxford Medical Sciences excels in REF 2014 exercise

Today’s Research Excellence Framework (REF 2014) results confirm the University of Oxford’s world leading position in medical sciences research.

Furthermore, the University overall has the largest volume of world leading research and impact submitted to the REF exercise.

The Department of Oncology is part of the Medical Sciences Division and submitted under Clinical Medicine, a unit of assessment in which we ranked top for overall quality.

Peter O'Neill

My interests over the years have focussed on the chemistry and biochemical pathways involved in the repair of radiation-induced DNA damage and more recently have focussed on clustered DNA damage.

RADVAN

EudraCT number: 2011-000661-12 
Sponsor: University of Oxford

A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases.

The aim is to compare whole brain radiotherapy (WBRT) with or without vandetanib in the treatment of patients with brain metastases from melanoma, in terms of progression free survival, overall survival and safety and tolerability of vandetanib in combination with radiotherapy.

Pages

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
Research
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.
Subscribe to Department of Oncology RSS